BioCardia Reports Third Quarter 2023 Business Highlights : v

SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

Related Keywords

Minnesota , United States , Japan , California , Canada , Maryland , Japanese , Miranda Peto , Peter Altman , David Mcclung , York Heart Association Class , Exchange Commission , Device Agency , Company Annual Report On Form , Maryland Stem Cell Research Fund , Biocardia Inc , Company Phase , Exchange Commission On , Medicaid Services , Chronic Myocardial Ischemia , Autologous Cell Therapy , Ischemic Heart Failure , Therapy Trial , Heart Failure , Data Safety Monitoring Board , Minnesota Living , Heart Failure Questionnaire , Six Minute Walk , Therapy Heart Failure Trial , Therapy System , Medical Device Agency , Allogeneic Cell Therapy , Cell Therapy , New York Heart Association Class , Heart Failure Phase , Chronic Myocardial Ischemia Phase , Roll In Cohort , Randomized Pivotal , Low Dose , Looking Statements , Quarterly Reports , Consolidated Financial Statements , Annual Report , Chief Financial , Nasdaq Bcda , Biocardia , Nc , Cda , Ardiamp , Ardiallo , Temcelltherapy , Linicaltrial , Earnings , Earningscall , Update , Quarterlyearnings ,